Skip to main content
Premium Trial:

Request an Annual Quote

Olympus, Cangen Biotechnologies, Harvard Bio, HealthLinx, Bruker Daltonics, Solexa, Sequenom, Roswell Park Cancer Institute


Olympus, Cangen to Co-develop 'Hybrid' DNA/Protein Microarray-based Test for Lung Cancer

Cangen Biotechnologies and Olympus plan to co-develop a hybrid DNA- and protein-based diagnostic that can detect early-stage lung cancer, the firms said this week.

The alliance will provide Cangen access to Olympus' microarray technology to enable the DNA-based portion of the test. Terms also call for Olympus to "refine" and "further develop" its microarray technology to help Cangen develop the hybrid test. Technical details were not disclosed.

"This collaboration complements development efforts for our microarray technology and affords us the opportunity to commercialize that technology," Hiroyuki Yoshimori, division manager of Biomedical Business Incubation Division in Olympus, said in a statement.

Financial terms were not released.

Harvard Bio Blames 'Service' for Genomic Solutions IPO Gaffe

Genomic Solutions' parent company, Harvard Biosciences, said neither firm is responsible for an erroneous IPO filing attributed to the subsidiary this week.

"Contrary to media reports, neither Harvard Bioscience nor its wholly owned subsidiary, Genomic Solutions, yesterday filed a Form S-1 registration statement with the SEC," Harvard Bio said in its statement, which appeared more than one day after multiple news outlets reported that the unit had filed for an initial public offering.

"We believe the source of the error was a service that reports on SEC filings. Generally, we have a policy of not commenting on media reports or rumors, however we have made an exception to correct these erroneous reports," Harvard Bio said.

News services, including GenomeWeb News, Pharmacogenomics Reporter's sister publication updated their reports this week to reflect that Genomic Solutions erroneously refiled its initial public offering documents from 2000. It was originally reported that the subsidiary was moving ahead with the $100 million IPO registration. The registration forms were later removed from the SEC's web site.

A Genomic Solutions spokesman had told Dow Jones that the forms it released were an "erroneous reissue." Harvard Bio's statement closes the saga.

Neither Genomic Solutions nor Harvard Bioscience returned GenomeWeb News' calls for comment.

Bruker's ClinProt Mass Spec Platform to Help HealthLinx Develop IVD Biomarker Assays

HealthLinx of Melbourne, Australia, will use Bruker Daltonics' mass spectrometry-based protein biomarker platform to develop diagnostic assays, the company said this week.

In collaboration with Bruker, HealthLinx plans to develop in vitro diagnostic tests for both research and clinical diagnostics using Bruker's MALDI-TOF mass spectrometer and its ClinProt magnetic bead sample preparation technology and software.

The first product to be developed is an ovarian cancer test based on four biomarkers discovered by HealthLinx. The company has also enlisted the Walter Eliza Hall Institute of Medical Research to develop monoclonal antibodies to these biomarkers, to be used with the Bruker platform. HealthLinx said it will seek FDA registration for the test "through industry partnerships for use as a pathology diagnostic."

Following validation, the companies will also seek to register the ClinProt platform as a diagnostic pathology device with the Australian government's Therapeutic Goods Administration.

Solexa Lays Off 17 Percent of Staff; Still Plans to Launch SBS Instrument by Year's End

Solexa has laid off approximately 25 employees, bringing its headcount to 116, following its merger with Lynx Therapeutics, the company said last week.

"Changes in product mix and operating improvements" were the chief causes of the restructuring, which mostly affected the company's genomics services business, which offers gene expression analysis based on Lynx's MPSS technology, according to the company statement.

However, that business unit will "remain a strategic part of the company" and is expected to create Solexa's first revenues from its Sequencing-by-Synthesis Cluster instrument for DNA sequencing and gene expression analysis. Solexa plans to place SBS-Cluster instruments in its genomics services facility by the end of the year and offer the instruments for sale in 2006, the company said.

Due to the lay-offs, which did not include members of senior management but affected positions in most functions, Solexa will record a non-recurring charge of approximately $350,000 in the second quarter.

Sequenom Sells MassArray Instrument to Roswell Park Cancer Institute

Sequenom has sold a MassArray genotyping instrument to the Roswell Park Cancer Institute, the San Diego-based company said this week.

The institute, based in Buffalo, NY, will initially use the system for pharmacogenomic studies in breast cancer patients to predict response to treatment, as well as to determine who is at risk for cardiovascular disese.

Sequenom's MassArray system analyzes DNA by mass spectrometry.

Filed under

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.